Barinthus Biotherapeutics (NASDAQ:BRNS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research report released on Monday morning, Benzinga reports. They currently have a $5.00 target price on the stock.

A number of other brokerages have also recently issued reports on BRNS. William Blair reissued an outperform rating on shares of Barinthus Biotherapeutics in a research report on Thursday, June 13th. Barclays reduced their target price on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an overweight rating for the company in a research report on Thursday, June 13th.

Barinthus Biotherapeutics Price Performance

BRNS stock opened at $1.33 on Monday. The company has a fifty day moving average price of $1.50 and a two-hundred day moving average price of $2.17. Barinthus Biotherapeutics has a one year low of $1.21 and a one year high of $5.10. The stock has a market cap of $51.91 million, a price-to-earnings ratio of -0.72 and a beta of -0.52.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01). Research analysts anticipate that Barinthus Biotherapeutics will post -1.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Alphabet Inc. acquired a new position in Barinthus Biotherapeutics in the second quarter valued at about $2,119,000. Catalina Capital Group LLC acquired a new position in Barinthus Biotherapeutics during the second quarter worth about $25,000. Ipswich Investment Management Co. Inc. acquired a new position in Barinthus Biotherapeutics during the second quarter worth about $32,000. M&G Plc acquired a new position in Barinthus Biotherapeutics during the second quarter worth about $7,276,000. Finally, BlueCrest Capital Management Ltd acquired a new position in Barinthus Biotherapeutics during the first quarter worth about $1,292,000. Institutional investors and hedge funds own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.